Kent Imaging names JCare sole distributor for SnapshotNIR in Hong Kong and Macau

By AI, Created 3:11 PM UTC, June 02, 2026, /AGP/ – Kent Imaging has signed a distribution agreement with JCare Medical Technology to sell SnapshotNIR in Hong Kong and Macau, extending the handheld tissue oxygenation imaging device’s reach in Asia-Pacific. The move gives JCare exclusive distribution rights and brings the FDA-cleared and CE-marked platform to clinicians in wound care, vascular and surgical settings.

Why it matters: - The agreement expands Kent Imaging’s Asia-Pacific footprint and gives clinicians in Hong Kong and Macau access to non-invasive, real-time tissue oxygenation imaging. - SnapshotNIR is designed to support bedside decisions in wound care, vascular care and surgery. - JCare’s role as sole distributor concentrates local sales and support through a single channel.

What happened: - Kent Imaging signed a new distribution agreement with JCare Medical Technology Co. Limited. - JCare is now the sole distributor of SnapshotNIR in Hong Kong and Macau. - Kent Imaging said the partnership is part of its continued expansion across Asia-Pacific. - JCare is headquartered in Kowloon, Hong Kong.

The details: - SnapshotNIR is a portable, handheld near-infrared spectroscopy imaging device. - The device measures tissue oxygen saturation, oxyhemoglobin, deoxyhemoglobin and total hemoglobin at the point of care. - SnapshotNIR auto-calibrates, which expands access for patients of nearly all skin tones. - The device is FDA-cleared and CE-marked. - The Hemoglobin View feature provides visual mapping and quantitative data on hemoglobin concentrations and tissue oxygenation. - Kent Imaging says SnapshotNIR is the only medical imaging device on the market offering this level of objective hemoglobin data at the bedside. - JCare distributes advanced wound care, compression therapy and related medical technology products across Hong Kong and Macau. - JCare was founded in 2017 and serves public hospital systems as well as private facilities. - JCare’s senior management team has more than 20 years of experience in global healthcare and pharmaceuticals. - Kent Imaging is based in Calgary, Alberta, Canada. - Kent Imaging designs, manufactures and markets medical devices for wound care, vascular and surgical specialties. - The Snapshot product suite also includes SnapshotGLO, a bacterial autofluorescence imaging device that received FDA 510(k) clearance in 2025. - SnapshotNIR was initially cleared by the FDA and Health Canada in 2017 and received CE marking in 2025.

Between the lines: - The deal gives Kent Imaging a local partner with an established wound care network in a market that values specialized medical distribution. - The focus on objective, real-time tissue viability data suggests Kent Imaging is targeting clinicians who want more measurable inputs for treatment decisions. - The company is using the Snapshot family to broaden its position in advanced imaging beyond oxygenation into bioburden detection.

What’s next: - Kent Imaging and JCare plan to introduce SnapshotNIR to clinicians in Hong Kong and Macau. - The device is expected to be used to identify compromised oxygenation, monitor healing trends, guide vascular referrals and inform surgical planning. - The companies will work together to bring the technology into wound care and surgical settings across the two markets.

The bottom line: - Kent Imaging is adding a dedicated distributor in Hong Kong and Macau to push SnapshotNIR deeper into Asia-Pacific clinical care.